Cited 106 times in

Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.

Authors
 Woo Young Sun  ;  Yu Kyung Lee  ;  Ja Seung Koo 
Citation
 JOURNAL OF TRANSLATIONAL MEDICINE, Vol.14(1) : 173, 2016 
Journal Title
JOURNAL OF TRANSLATIONAL MEDICINE
Issue Date
2016
MeSH
Antibodies, Monoclonal/metabolism ; Antibodies, Neoplasm/metabolism* ; B7-H1 Antigen/metabolism* ; Disease-Free Survival ; Humans ; Immunohistochemistry ; Multivariate Analysis ; Prognosis ; Reproducibility of Results ; Triple Negative Breast Neoplasms/immunology ; Triple Negative Breast Neoplasms/metabolism* ; Triple Negative Breast Neoplasms/pathology
Keywords
Breast cancer ; Immunohistochemistry ; Monoclonal antibody ; PD-L1 ; Triple negative
Abstract
BACKGROUND: To date, there are no effective therapeutic targeting agents for triple-negative breast cancer (TNBC), and PD-L1 has presented potential as an effective marker of immunotherapeutic agents. The aim of this study was to evaluate the expression of PD-L1 by three different immunohistochemical antibodies in TNBC.
METHODS: Interpretation of all three PD-L1 antibodies showed good concordance among three readers (kappa value >0.610) in both cancer cells and immune cells. Using a tissue microarray (TMA) constructed from 218 cases of TNBC, we performed immunohistochemical staining using three of the most popular commercially used PD-L1 monoclonal antibodies (clones 28-8, E1L3N and SP142) in cancer cells and immune cells.
RESULTS: Using various cut-off values of previous studies (1, 5, 10 and 50 %), the expression rates in cancer cells were: PD-L1 (E1L3N) (14.7, 14.7, 11.0, 2.3 %), PD-L1 (28-8) (13.3, 12.4, 10.1, 1.8 %), and PD-L1 (SP142) (11.5, 11.0, 6.9, 0.5 %), respectively. At the 5 % cut-off value, the discordance rate among the three antibodies was 6.0-10.6 % and was highest between PD-L1 (SP142) and the other two antibodies. The expression rates in immune cells were PD-L1 (E1L3N) (37.6 %), PD-L1 (28-8) (36.7 %), and PD-L1 (SP142) (19.3 %), and the discordance rate among the three antibodies ranged from 13.8 to 24.8 % and was also highest between PD-L1 (SP142) and the other two antibodies. Among stromal histologic types, higher PD-L1 expression in cancer cells and immune cells was measured in inflammatory-type (p < 0.05). The absence of PD-L1 (28-8) staining in immune cells was associated with shorter disease free survival (DFS) and overall survival (OS) (p = 0.043, and p = 0.021) in univariate analyses, and with shorter OS in multivariate Cox analysis (hazard ratio: 5.429, 95 % CI 1.214-24.28, p = 0.027).
CONCLUSIONS: PD-L1 detection in cancer cells and immune cells varied by antibody clone. The greatest amount of staining occurred with PD-L1 (E1L3N), followed by PD-L1 (28-8) and PD-L1 (SP142). The concordance rate among monoclonal PD-L1 antibodies was higher between PD-L1 (28-8) and PD-L1 (E1L3N). To determine the gold standard antibody and the most appropriate cut-off value, further study of the clinical trial group treated with PD-L1 inhibitor is necessary.
Files in This Item:
T201601853.pdf Download
DOI
10.1186/s12967-016-0925-6
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Koo, Ja Seung(구자승) ORCID logo https://orcid.org/0000-0003-4546-4709
Lee, Yu Kyung(이유경)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/146960
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links